title: [Pseudophakic cystoid macular oedema].
abstract: Pseudophakic cystoid macular oedema is still a relevant clinical disease entity although major progress in modern cataract surgery has been made within the last decades. The relevance is attributed to the large number of cases that are performed each year. Even after uneventful surgery, a pseudophakic cystoid macular oedema can develop and may lead to severe and lasting visual impairments. In respect to the pathophysiology, four consecutive steps have to be considered: (i) surgical procedure-related induction and release of various inflammation mediators into the anterior chamber; (ii) removal of the physiological lens barrier between the anterior and posterior segments of the eye, leading consecutively to an increase in diffusion rate in either direction; (iii) local action of the inflammation mediators towards the macular area; and (iv) increased vitreoretinal traction due to the anteriorly oriented drive of the vitreous. To prevent the development of a pseudophakic cystoid macular oedema, systemic and ocular pathologies should be treated consequently prior to surgery. Furthermore, an individual risk profile of each patient needs to be evaluated to define the best pre- and postsurgical medical treatment. A less traumatic surgical approach can help to prevent macular oedema development additionally. The diagnosis is made by performing biomicroscopy, fluorescence angiography and optical coherence tomography as well as by evaluating the patients' major complaints. Standard operation procedures or recommended guidelines by the specialised eye associations to prevent and treat pseudophakic cystoid macular oedema are not available up to date. A synopsis of recommendations in the literature suggests a step-wise treatment regimen, including topical medical treatment on the one hand and a surgical approach on the other hand as well as a combination of both, if needed. Topical medical treatment options include the use of non-steroidal, corticosteroid and/or carbonic anhydrase inhibitor eye drops. Surgical interventions include pars plana vitrectomy.
authors.affiliation: Augenklinik, Universitätsklinikum Giessen und Marburg GmbH, Marburg, Deutschland. thomas.bertelmann@staff.uni-marburg.de
authors.forename: T
authors.initials: T
authors.lastname: Bertelmann
authors.forename: M
authors.initials: M
authors.lastname: Witteborn
authors.forename: S
authors.initials: S
authors.lastname: Mennel
mesh_terms: D006801:Humans; D008269:Macular Edema / Q000150:complications / Q000175:diagnosis* / Q000628:therapy*; D019591:Pseudophakia / Q000150:complications / Q000175:diagnosis* / Q000628:therapy*